Loading organizations...
§ Private Profile · San Francisco, CA, USA
Life science tools company developing automated benchtop systems for extracellular vesicle isolation for researchers and diagnostics.
Hermes Biosciences, a San Francisco-based venture-backed life science tools company, develops an automated benchtop system for isolating extracellular vesicles (EVs) from biological samples with high yield and purity. This innovative nanofiltration technology, invented by co-founder Professor Utkan Demirci of Stanford University School of Medicine, delivers approximately 10 times more vesicles than conventional ultracentrifugation, preserving vesicle integrity and molecular content. The platform supports research, diagnostic development, and clinical applications. Founded in 2024 by Professor Demirci and General Inception, the company recently secured seed-stage funding led by Genoa Ventures, with participation from Paladin Capital Group and Vertical Venture Partners, following pre-seed support from General Inception. CEO Paco Cifuentes leads Hermes Biosciences, which aims to deliver its first commercial instrument in 2026, serving clinical researchers, pharmaceutical companies, and academic institutions.
Hermes Biosciences has raised $6.0M across 1 funding round.
Hermes Biosciences has raised $6.0M in total across 1 funding round.
Hermes Biosciences has raised $6.0M across 1 funding round. Most recently, it raised $6.0M Seed in November 2025.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Nov 19, 2025 | $6M Seed | Vikram Chaudhery | Paladin Capital Group, Vertical Venture Partners | Announced |
Hermes Biosciences has raised $6.0M in total across 1 funding round.
Hermes Biosciences's investors include Vikram Chaudhery, Paladin Capital Group, Vertical Venture Partners.